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Cytopathologist review of thyroid US has been proposed to be useful in diagnosis and 
patient triage. This editorial explores the implications for practicing cytopathologists of 
integrating US review into thyroid FNA diagnosis.   At present there is no agreed upon 
system for combining cytologic and ultrasound (US) features and communicating those 
results as a single report.  If cytologists are performing tasks that require expertise in US 
interpretation, then they should know and be fully conversant with US interpretation.  
Whether cytologists performing aspirations require expertise in US interpretation is not 
clear.  Regardless, cytologists should avoid using US results to alter their cytologic 
interpretations unless they clearly communicate that this is what they are doing.  An 
evidence-based integrated reporting system that would allow cytologists to clearly 
explain to other physicians exactly how they reached their interpretation might  
provide value beyond current standard practice. 
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Condensed Abstract: Cytopathologist review of thyroid US has been proposed to be 
useful in diagnosis and patient triage. This editorial looks more closely at the implications 
of this for practicing cytologists.   
  
 
Fine needle aspiration (FNA) biopsy of the thyroid is the single most useful 
diagnostic tests to evaluate which patients with thyroid nodules should undergo surgery. 
The results are reported as recommended by the Bethesda System1 or  other similar 
terminologies e.g. Royal College of Pathologists (RCPath) ‘Thy’ or Italian TIR 
terminologies2.  The cytology report is then evaluated along with other clinical and 
laboratory information, including, age, sex, physical examination, serum chemistry and 
hormone levels, and imaging features.  The imaging features, most commonly the 
ultrasound (US) features, but also sometimes PET-CT, CT or MRI are used to select 
patients who should undergo FNA, in some cases to target lesion(s) while performing 
FNA, and in the selection of patients who may need repeat FNA or surgery.   
 
The US features of a given lesion are therefore critical for managing patients with thyroid 
nodules.  US evaluation is typically performed by either clinicians or radiologists.  At 
present there are at least 5 internationally used systems for  reporting US results: the 
American Thyroid Association score3,4, the ACR TIRADS4, the European EU-TIRADS5, 
the South Korean K-Tirads6, the Chilean TIRADS7 and the British Thyroid Association 
‘U’ classification8,9.   These systems although quite similar are not identical. All aim to 
give an indication of the clinical risk by evaluation of a wide variety of features, 
including shape, margin, calcifications, hypo-echogenicity, solid vs. cystic features, 
stiffness/elastographic features, and vascularity.  Other features that have been suggested 
to be of value in the US evaluation of thyroid nodules include the use of contrast 
enhanced US10-13, and Doppler imaging14.  Depending on the US risk stratification score, 
different size cut-offs for FNA are defined in each TIRADS system, in most cases only 
for lesions greater than 1cm3-5.   In addition, lesion size is strongly correlated with the 
sensitivity of FNA15.  However, whether the risk of malignancy for lesions greater than 1 
cm can be correlated with size is less clear 16-18.  Because of these many features, the US 
evaluation of thyroid nodules requires considerable training, skill and experience, and is 
to some extent subjective. There is variation even among experienced clinicians about 
how these criteria are interpreted and applied.  Some have written that cytopathologist 
review of thyroid US is extremely useful and can be helpful in triaging patients 19-22. This 
editorial looks more closely at the implications of this for practicing cytologists in three 
different circumstances: participating in the management of thyroid nodules after FNA, 
deciding which nodules should be submitted to FNA and how to perform an aspiration 
biopsy, and evaluating the cytological diagnosis with respect to the US pattern. 
.  
 
 Most thyroid nodules are initially evaluated by clinicians and not by cytologists. 
The decision to recommend follow-up, repeat aspiration, or surgery is also usually made 
by clinicians rather than by cytologists. If a cytologist is part of a multidisciplinary team 
(MDT) that discusses management of patients with thyroid nodules, then some 
knowledge of thyroid nodule US features may be helpful to the participating cytologist. 
Opponents of this view would argue that detailed knowledge of US features is not 
required by cytologists since MDTs comprise clinicians and radiologists whose role it is 
to provide expertise in US interpretation. However, in the experience of some of the 
authors (DP, GR) many FNA cases, particularly in the lower risk of malignancy US or 
FNA categories (The Bethesda System for Reporting Thyroid Cytopathology [TBSRTC] 
categories- III-IV, equivalent to UK RCPath Thy 3a-Th 3f) are not listed for MDT 
discussion because of time and resource constraints23. The UK Royal College of 
Pathologists Guidance only recommends mandatory MDT discussion of higher risk Thy 
4 and Thy 5 aspirates, equivalent to TBSRTC  categories V and VI24.  In such cases, a 
cytologist might attempt to select a subset of patients from the lower risk group who 
might benefit from further discussion at MDT conference.  In this situation a cytologist 
would then be performing a task that clinicians most often do, so an understanding of the 
US characteristics to the same extent as a clinician would appear appropriate.  In the 
opinion of some of the authors (DP, GR), the most important US feature of a thyroid 
nodule is whether it is solid, purely cystic, or partially cystic/solid.  Specifically, if there 
is a solid component, a borderline or non-diagnostic aspirate is unlikely to be 
representative and re-aspiration may then be helpful19,25.  A description of how one 
author (DNP) routinely integrates US into his daily practice is shown in Table 1. 
 
Alternatively, it is not uncommon for cytopathologists to perform US guided 
FNA21,26-29, and a course on the subject is offered by the College of American 
Pathologists30.  Cytopathologist guided US thyroid FNA has very low rates of non-
diagnostic aspirates, typically 3-7%27.  If a cytologist is selecting nodules to aspirate, then 
adequate knowledge to evaluate the US results at the same level as radiologists and 
clinicians is important.  If the cytologist is simply using the US to identify the nodule and 
guide the needle to the appropriate area of a nodule that is selected for biopsy by 
someone else, then knowledge of the US technique and results that are relevant for this 
task would be appropriate.  Any supporting documentation for the procedure should 
clearly indicate which of these 2 scenarios applied in the acquisition of the sample. 
 
 
 The setting in which the use of US features is more controversial is in the actual 
evaluation of the cytologic diagnosis of the nodule. This scenario most commonly arises 
in evaluating the adequacy of an aspirate or in refining classification of an indeterminate 
aspirate.   In settings where there may be an issue with adequacy, rapid on site evaluation 
(ROSE) can be of value in increasing the adequacy rate 31.  However, the benefit of 
ROSE in settings with experienced practitioners who already have a high adequacy rate is 
limited 32.  Certainly ROSE allows one to immediately assess adequacy and do more 
passes to obtain additional material to achieve adequacy.  In a cystic lesion, the needle 
may be directed into a more solid area to increase the yield of cellular material.  
However, some cystic lesions will remain non-diagnostic due to an absence of epithelial 
cells or colloid.  While the TIRADS systems have a defined method to manage these 
patients, a cytologist with knowledge of US evaluation might be tempted to seek to 
combine the cytologic and US evaluation into a single report that they might regard as 
“adequate” based on primarily imaging criteria rather than cellularity.  Indeed, it is the 
experience of one of the authors (AR) that some cytologists do diagnose an aspirate 
without any epithelial cells as ‘adequate’ if the US characteristics are those of a simple 
cyst.  If the report does not clearly indicate that assessment of adequacy is based on the 
imaging characteristics there is a risk that the follow-up recommendation (i.e. repeat 
aspiration or no further follow-up) may be determined based on the impression that 
adequacy was based on cytologic criteria rather than the imaging characteristics, and the 
follow-up or clinical management may be different.  Cytopathologists undertaking US 
guided thyroid FNA therefore should adhere to the strict cellular adequacy criteria as 
detailed by either the relevant reporting terminology system, evidence-based criteria33-35, 
or clearly state how their evaluation of adequacy was determined.  In contrast, some 
authors have suggested that cystic lesions deserve their own separate diagnostic category 
36,37, which would at least make the way the diagnosis of adequacy was made clearer. 
 
 Similarly, even though clinicians appropriately review the US findings when 
trying to determine how to manage patients with an indeterminate aspirate, some 
studies38-43 but not all43-46 suggest that this information is of limited value.  In general, it 
is difficult to construct reproducible criteria that would allow one to consistently 
reclassify an indeterminate aspirate as benign based on US features alone.  However, 
specific US features may be more useful in specific settings to reliably reclassify a subset 
of indeterminate cases as benign.  If a cytologist with extensive US knowledge 
undertakes and reports an US guided FNA and the cytologist has some diagnostic 
uncertainty as to the cytologic diagnosis, it is possible that the cytologist may, possibly 
unconsciously, be influenced by cognitive bias, and use the combination of the US 
characteristics and the cytological findings to further “refine” the cytologic diagnosis into 
a more determinate result.  For example, it is well documented that the diagnosis of 
atypical/suspicious follicular lesions (i.e. a sample with microfollicles) is associated with 
a very low risk of malignancy if the nodule is less than 1 cm in size47. As a result, a 
cytologist may be tempted to incorporate knowledge of the size of a lesion into the 
cytology report and report the lesion in a lower malignancy risk category, TBSRTC 
category II or III, UK RCPath Thy 2 or Thy 3a.  However, the same nodule may grow 
larger than 1 cm and if re-aspirated will still show the same microfollicular pattern.  
Because of the larger lesion size the cytologist may report the lesion in a higher risk 
category48; TBSRTC Category IV, UK RCPath Thy 3f.  As a result, the clinician might 
assume that the lesion not only had grown in size but had also changed its cytologic 
features over time which would not be true and also might result in a different 
management strategy.  Similarly, some US features have been noted to be inconsistent 
with a diagnosis of Non invasive follicular thyroid neoplasm with papillary-like nuclear 
features (NIFTP)49.  Most clinicians would assume that if a cytologist chooses to make a 
definitive diagnosis of papillary carcinoma it is based on cytologic criteria, not US 
features, and if their assessment of those US features were different than the cytologist’s 
assessment management may be affected.  Another example worth considering is when a 
diagnosis of Hashimoto’s thyroiditis is contemplated and is potentially used for calling an 
aspirate benign vs AUS vs suspicious for a Hurthle cell neoplasm. If the evidence for 
thyroiditis on the slide is weak, some pathologists may be influenced about the presence 
of a description of a diffusely heterogeneous gland on US. 
 
 
 Finally, the level of experience cytologists have with US interpretation may vary 
considerably, even though they may be “fully conversant” with the TIRADS criteria.  If a 
cytologist alters their cytologic interpretation based on their interpretation of the US 
features, this may create a problem if a clinician with more experience does not agree 
with that US interpretation.    Alternatively, some cytologists with enormous US 
experience20 may use that experience to alter their cytologic interpretation of the case in 
ways that are difficult to defend based on evidence based criteria alone.   After all, some 
studies38-43 but not all43-46 suggest that this information is of limited value.  Different 
clinicians may appreciate a cytologist taking this approach more or less depending on a 
variety of factors.    At best, the knowledge that is included in that experience is lost to 
the cytologist’s colleagues and future generations of cytologists if it is not published.  At 
worst, the conclusions that the cytologist reaches based on their experience in the absence 
of any confirmatory data may simply be wrong.   Indeed, one of the strengths of the Paris 
criteria for urine cytology50 was to finally put to rest some “diagnostic criteria” that past 
leaders in the field had promoted based on their experience alone and which were never 
able to be confirmed. 
 
  As a result, when a cytologist interprets US results either for performing 
aspirations or in evaluating patients for management, there is a need to clearly define 
exactly what information is being obtained from the US and which information is being 
obtained from the aspirate.  One of the strongest arguments for standardized 
terminologies such as the TBSRTC and the TIRADS systems is that use of a standardized 
terminology facilitates communication between physicians.  At present there is no agreed 
system for combining cytologic and US features and communicating those results as a 
single report.  Such a system might have some advantages over the two separate systems 
that are currently used.  When authors say that it useful for cytologists to know the detail 
of the US interpretation, it is important to clarify what exactly they mean.  If a cytologist 
is only rendering cytologic interpretations and is not reviewing the US, then interpreting 
the specimen along the lines defined in TBSRTC and having no particular knowledge of 
the US features is perfectly reasonable.  If cytologists are performing tasks that require 
expertise in US interpretation, then the answer is yes of course they should know and be 
fully conversant with US interpretation.  Whether cytologists performing aspirations 
require expertise in US interpretation is not clear.  However, cytologists should avoid 
using US results to alter their cytologic interpretations unless they clearly communicate 
that this is what they are doing.  An evidence-based reporting system that would allow 
cytologists to clearly explain to other physicians exactly how they reached their 
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